7Baggers

We provide you with 20 years of free, institutional-grade data for RVMD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RVMD. Explore the full financial landscape of RVMD stock.

Reported DateCIKTickerType
2025-08-061628171RVMD10-QUrl
2025-05-071628171RVMD10-QUrl
2025-02-261628171RVMD10-KUrl
2024-11-061628171RVMD10-QUrl
2024-08-071628171RVMD10-QUrl
2024-05-081628171RVMD10-QUrl
2024-02-261628171RVMD10-KUrl
2023-11-061628171RVMD10-QUrl
2023-08-081628171RVMD10-QUrl
2023-05-081628171RVMD10-QUrl
2023-02-271628171RVMD10-KUrl
2022-11-071628171RVMD10-QUrl
2022-08-091628171RVMD10-QUrl
2022-05-091628171RVMD10-QUrl
2022-02-281628171RVMD10-KUrl
2021-11-101628171RVMD10-QUrl
2021-08-111628171RVMD10-QUrl
2021-05-101628171RVMD10-QUrl
2021-03-021628171RVMD10-KUrl
2021-02-011628171RVMDS-1Url
2020-11-121628171RVMD10-QUrl
2020-08-101628171RVMD10-QUrl
2020-07-061628171RVMDS-1Url
2020-05-141628171RVMD10-QUrl
2020-03-301628171RVMD10-KUrl
2020-01-171628171RVMDS-1Url

Revolution Medicines, Inc
(NASDAQ:RVMD) 

RVMD stock logo

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gyne...

Founded: 2014
Full Time Employees: 117
CEO: Mark A. Goldsmith  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about RVMD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.